Search results
3 sie 2023 · While the drug—commonly known by brand names such as Ozempic and Wegovy — helps reduce blood glucose to normal levels, it also slows the passage of food through the stomach and reduces...
10 lut 2021 · Our trial showed that among adults with overweight or obesity (without diabetes), once-weekly subcutaneous semaglutide plus lifestyle intervention was associated with substantial, sustained ...
Our systematic review aims to analyze the efficacy of semaglutide, a GLP-1RA in treating obesity. We searched PubMed, Science Direct, and Google Scholar databases to review and distill full-text articles based on the eligibility criteria and involved 12 papers of clinical trials.
18 paź 2022 · The Semaglutide Treatment Effect in People with obesity (STEP) clinical trial programme is evaluating once-weekly subcutaneous semaglutide 2.4 mg (a glucagon-like peptide-1 analogue) in people with overweight or obesity.
10 paź 2022 · In summary, in adults with overweight (with at least one weight-related comorbidity) or obesity, semaglutide treatment led to substantial, sustained weight loss over 104 weeks versus placebo.
13 maj 2024 · Semaglutide was associated with fewer serious adverse events. For each BMI category (<30, 30 to <35, 35 to <40 and ≥40 kg m −2) there were lower rates (events per 100 years of observation) of...
30 paź 2024 · Semaglutide, administered subcutaneously once weekly, is a GLP-1 receptor agonist that is approved in several countries for weight management in persons with a body-mass index (BMI; the weight in...
